Journal Watch · Frontiers in Immunology · 2026
Serum complement system activation in normal healing and atrophic non-union of human long bone fractures.
This data will offer fresh avenues for utilizing complement system components, such as follow-up biomarkers and therapeutic targets, in bone injuries and diseases.
TL;DR
This data will offer fresh avenues for utilizing complement system components, such as follow-up biomarkers and therapeutic targets, in bone injuries and diseases.
Key findings
- In fracture non-union, the serum MASP1 level was significantly higher than that of normal fracture healers and healthy controls.
- The IPA analysis showed a link between MASP1 as a part of the lectin pathway and damage in bone and cartilage.<h4>Discussion</h4>Collectively, our data indicate temporal changes of the serum complement system with activation via the classical pathway, particularly during the inflammatory phase of normal healing of human bone fractures.
- Furthermore, systemic MASP1 levels were high in non-united fractures, indicating that the lectin pathway plays a unique role in abnormal fracture healing.
- This data will offer fresh avenues for utilizing complement system components, such as follow-up biomarkers and therapeutic targets, in bone injuries and diseases.
What they did
The serum samples were processed using mass spectrometry to quantify the complement protein expression. The ELISA was used for validation. Ingenuity Pathway Analysis (IPA) software was used for molecule-pathway interactions.<h4>Results</h4>The classical complement pathway components, complement C1s and C1r, were significantly increased during the inflammation phase of normally healed fractures but reduced subsequently. The levels of serum C3, C3a, and C9 were significantly greater in the inflammatory phase than in the other phases. No significant differences were observed for other complement pathway components, complement factor B (CFB), complement factor H and I (CFH, CFI), ficolin 2 and 3 (FCN2, FCN3) and mannan-associated serine protease-1 (MASP1) when comparing the three phases.
Full abstract (original)
Background: <h4>Introduction</h4>The complement system has an important role in physiological bone healing, as studied mainly in animal models and local bone tissues. However, the role of the complement system in human fractures, particularly at the systemic level, remains insufficiently characterized. This study aimed to investigate the activation levels of the serum complement system during three healing phases (inflammation, repair and remodeling) of normal healing of long bone fractures and in patients diagnosed with fracture non-union.<h4>Methods</h4>Blood samples were obtained from two groups of long bone fracture patients (normal healers and non-union) and healthy controls with no fractures. Blood samples from patients with normally healed fractures were collected at 1 week, 1 month, and 4-6 months post-fracture. Blood samples from patients diagnosed with non-union were collected at 1-year post-fracture.
What they did: The serum samples were processed using mass spectrometry to quantify the complement protein expression. The ELISA was used for validation. Ingenuity Pathway Analysis (IPA) software was used for molecule-pathway interactions.<h4>Results</h4>The classical complement pathway components, complement C1s and C1r, were significantly increased during the inflammation phase of normally healed fractures but reduced subsequently. The levels of serum C3, C3a, and C9 were significantly greater in the inflammatory phase than in the other phases. No significant differences were observed for other complement pathway components, complement factor B (CFB), complement factor H and I (CFH, CFI), ficolin 2 and 3 (FCN2, FCN3) and mannan-associated serine protease-1 (MASP1) when comparing the three phases.
Results & conclusions: In fracture non-union, the serum MASP1 level was significantly higher than that of normal fracture healers and healthy controls. The IPA analysis showed a link between MASP1 as a part of the lectin pathway and damage in bone and cartilage.<h4>Discussion</h4>Collectively, our data indicate temporal changes of the serum complement system with activation via the classical pathway, particularly during the inflammatory phase of normal healing of human bone fractures. Furthermore, systemic MASP1 levels were high in non-united fractures, indicating that the lectin pathway plays a unique role in abnormal fracture healing. This data will offer fresh avenues for utilizing complement system components, such as follow-up biomarkers and therapeutic targets, in bone injuries and diseases.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1825939 · PubMed 42344890.
Why it matters for pharma & biotech
- Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: cell therapy (CAR-T / engineered cells)
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
This data will offer fresh avenues for utilizing complement system components, such as follow-up biomarkers and therapeutic targets, in bone injuries and diseases.
What type of study is this?
It is a clinical study, published in Frontiers in Immunology in 2026. The serum samples were processed using mass spectrometry to quantify the complement protein expression.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1825939. PubMed ID: 42344890. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/serum-complement-system-activation-in-normal-healing-and-atrophic-non-un-825939/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides